> ## Content Index
> Fetch the complete content index at: https://members.americanhealthintel.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Curium to acquire Lantheus for up to $114.50/share, ~$8B, largest radiopharma deal ever
- URL: https://members.americanhealthintel.com/2026-08-05-serviceline/
- Published: 2026-08-05T21:06:22.000Z
- Updated: 2026-08-05T21:06:22.000Z
- Description: Plus: American Oncology Network now runs 9 radioligand therapy centers, up from 1 in 2023. The day's rules, money, and enforcement, sourced and tiered below.
- Author: American Health Intel

Plus: American Oncology Network now runs 9 radioligand therapy centers, up from 1 in 2023\. The day's rules, money, and enforcement, sourced and tiered below.

| American Health Intel Rules · Money · Medicine · Decoded daily The Service Line Wednesday, August 5, 2026 Curium to acquire Lantheus for up to $114.50/share, \~$8B, largest radiopharma deal ever Plus: American Oncology Network now runs 9 radioligand therapy centers, up from 1 in 2023\. The day's rules, money, and enforcement, sourced and tiered below. ![](https://americanhealthintel.com/email/pulse-divider.png) Record Curium, a manufacturer of the radioactive drugs used to find and treat cancer, agreed to buy Lantheus, maker of the leading prostate cancer PET scan, for up to 114.50 dollars a share, about 8 billion dollars total. Announced August 3, 2026, the largest deal in radiopharmaceutical industry history. Lantheus's PYLARIFY scan alone made 240.9 million dollars in Q1 2026\. Deal expected to close first half of 2027. Record American Oncology Network, a network of community cancer practices, said it now operates 9 centers offering radioligand therapy, a targeted radiation cancer treatment, up from just 1 center in 2023. Announced July 23, 2026, with 5 more centers in development and two new physician leaders overseeing radiology and radiation oncology. Shows delivery capacity concentrating alongside manufacturing. Also today CMS CY2027 physician fee schedule proposes 340B repository reporting and doubled ACO E/M bonus [Read](https://americanhealthintel.com/editions/2026-08-05-serviceline/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#cy2027-mpfs-oncology-g2211-340b) GSK wins first lung cancer approval with zidesamtinib for ROS1-positive NSCLC [Read](https://americanhealthintel.com/editions/2026-08-05-serviceline/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#gsk-zidesamtinib-jideytro-approval) 374Records$31.6BEnforcement17Deadlines110Rules [Read this issue + the trackers](https://americanhealthintel.com/editions/2026-08-05-serviceline/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) Pick your field on the site and every story tells you what it means for you. Reply to this email and tell us what you want covered. We read everything. We show our work. We score our own calls. [Track record](https://americanhealthintel.com/ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Calendar](https://americanhealthintel.com/calendar/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Enforcement](https://americanhealthintel.com/enforcement/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [X](https://x.com/amhealthintel?ref=members.americanhealthintel.com) · [LinkedIn](https://www.linkedin.com/company/american-health-intel?ref=members.americanhealthintel.com) News and analysis, not legal, medical, coding, or investment advice.You subscribed at americanhealthintel.com · [Unsubscribe](%%{unsubscribe%5Furl}%%) |
| ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |